Literature DB >> 18361411

Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.

Akio Horiguchi1, Rong Zheng, Ruoqian Shen, David M Nanus.   

Abstract

BACKGROUND: The neurofibromatosis 2 (NF2) tumor suppressor gene product merlin is an important regulator of contact-dependent cell proliferation. Phosphorylation of merlin at serine 518 (Ser518) by the Rac effector p21-activated kinase (PAK) inactivates merlin's growth suppressing function, and is regulated by cell-culture conditions, including cell density, cell/substrate attachment, and growth factor availability. We examined the regulation of merlin expression and merlin phosphorylation in prostate cancer cells.
METHODS: Phosphorylation of merlin in five prostate cancer cell lines (LNCaP, DU145, PC3, 22RV1, and LAPC-4) was examined by Western blotting using anti-phospho-merlin (Ser518) antibody. The activity of PAK, an upstream regulator of merlin phosphorylation, was measured by Western blotting using phospho-PAK (Ser141) antibody. The effects of various cell-culture conditions on the phosphorylation levels of merlin and PAK were analyzed.
RESULTS: Both merlin expression and phosphorylation were low in LNCaP, PC3, 22RV1, and LAPC-4 prostate cancer cells. In DU145 cells, total and phosphorylated merlin were abundant, but phosphorylation was not inhibited by high cell density, serum withdrawal, the addition of hyaluronic acid or inhibition of CD44 expression, all of which are reported to inhibit merlin phosphorylation in non-neoplastic cells. PAK activation was elevated in DU145 cells and the addition of a PAK-specific inhibitor peptide but not the Rac1-specific inhibitor NSC23766 inhibited both PAK and merlin phosphorylation.
CONCLUSIONS: Merlin is inactivated in DU145 prostate cancer cells by PAK-mediated constitutive phosphorylation, identifying a novel mechanism of merlin inactivation in neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361411     DOI: 10.1002/pros.20760

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

1.  Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.

Authors:  Kui Yang; Yaqiong Tang; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

2.  Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis.

Authors:  Emily E Bosco; Wenjun Ni; Lei Wang; Fukun Guo; James F Johnson; Yi Zheng
Journal:  Blood       Date:  2010-02-23       Impact factor: 22.113

3.  Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells.

Authors:  Anaid Benitez; Travis J Yates; Luis E Lopez; Wolfgang H Cerwinka; Ashraf Bakkar; Vinata B Lokeshwar
Journal:  Cancer Res       Date:  2011-05-09       Impact factor: 12.701

4.  miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.

Authors:  Okay Saydam; Ozlem Senol; Thomas Würdinger; Arda Mizrak; Gokhan Baris Ozdener; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Anna M Krichevsky; Nurten Saydam; Gary J Brenner; Xandra O Breakefield
Journal:  Cancer Res       Date:  2010-12-13       Impact factor: 12.701

5.  Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma.

Authors:  Fabiana C Morales; Jennifer R Molina; Yuho Hayashi; Maria-Magdalena Georgescu
Journal:  Neuro Oncol       Date:  2010-02-14       Impact factor: 12.300

Review 6.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

7.  Therapeutic profile of single-fraction radiosurgery of vestibular schwannoma: unrelated malignancy predicts tumor control.

Authors:  Berndt Wowra; Alexander Muacevic; Christoph Fürweger; Christian Schichor; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2012-05-03       Impact factor: 12.300

8.  The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas.

Authors:  Cailei Zhao; Qian Chen; Chunde Li; Jian Yang; Cong Li; Yangyang Zhou; Jianxiang Liao
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

9.  Differential requirement for MEK Partner 1 in DU145 prostate cancer cell migration.

Authors:  Electa R Park; Ashok K Pullikuth; Evangeline M Bailey; Donald E Mercante; Andrew D Catling
Journal:  Cell Commun Signal       Date:  2009-11-23       Impact factor: 5.712

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.